e-learning
resources
Paris 2018
Monday, 17.09.2018
News on the diagnosis of idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
H. Wu (Lancaster, United Kingdom), J. Wingfield-Digby (Lancaster, United Kingdom), T. Gatheral (Lancaster, United Kingdom)
Source:
International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Session:
News on the diagnosis of idiopathic interstitial pneumonia
Session type:
Thematic Poster
Number:
2934
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Wu (Lancaster, United Kingdom), J. Wingfield-Digby (Lancaster, United Kingdom), T. Gatheral (Lancaster, United Kingdom). Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?. 2934
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Is the severity of oxidative stress different in patients with end stage chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation?
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007
Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept